Novartis AG 2022 IR
The report highlights Novartis' transformation into a focused, innovative medicines company in 2022, including the planned spin-off of its Sandoz division. The company delivered solid financial performance with USD 50.5 billion in net sales and USD 16.7 billion in core operating income. Key achievements include reaching 54.6 million patients through access programs and reducing greenhouse gas emissions in its own operations by 49% compared to a 2016 baseline. Additionally, Novartis advanced its R&D pipeline with 23 approvals in major markets and committed USD 250 million to research into malaria and neglected tropical diseases.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2022
Type: IR
Pages: 96
Back to company
Novartis AG
Integrated Report
The report highlights Novartis' transformation into a focused, innovative medicines company in 2022, including the planned spin-off of its Sandoz division. The company delivered solid financial performance with USD 50.5 billion in net sales and USD 16.7 billion in core operating income. Key achievements include reaching 54.6 million patients through access programs and reducing greenhouse gas emissions in its own operations by 49% compared to a 2016 baseline. Additionally, Novartis advanced its R&D pipeline with 23 approvals in major markets and committed USD 250 million to research into malaria and neglected tropical diseases.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees